Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070046 | 0.91 | THRA (0.33) | MMP9MMP1MMP13ADAM17MMP2 | |
| SCHEMBL369106 | 0.85 | CYP19A1 (0.42) | MMP9MMP13ADAM17CYP19A1KMT2A | |
| SCHEMBL12894144 | 0.83 | MAPT (0.36) | KMT2A | |
| SCHEMBL15101373 | 0.82 | MET (0.30) | — | |
| SCHEMBL10069877 | 0.82 | THRA (0.34) | THRATHRB | |
| SCHEMBL10070422 | 0.76 | TLR7 (0.31) | — | |
| SCHEMBL10070426 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL10069879 | 0.75 | TYK2 (0.32) | — | |
| SCHEMBL10071008 | 0.75 | ALDH1A1 (0.33) | MMP9MMP1MMP13ADAM17KMT2A | |
| SCHEMBL10069908 | 0.74 | KDM4E (0.32) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | MMP9 2836/4885MMP1 3191/4885MMP13 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.